Yulseung Sung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yulseung Sung has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Jung Min Han
Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Republic of Korea
11 shared publications - Hee Chan Yoo
College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea
7 shared publications - Ya Chun Yu
Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Republic of Korea
7 shared publications - Kibum Kim
Interdisciplinary Program of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University, Seoul, South Korea
5 shared publications - Seung Joon Park
Interdisciplinary Program of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University, Seoul, South Korea
5 shared publications - Do Sik Min
College of Pharmacy, Yonsei University, Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea
3 shared publications
Latest Publications
- Open Access
Synthesis-aware generative design in trillion-scale chemical spaces for automated drug discovery
Autonomous drug discovery via generative molecular design is critically bottlenecked by the production of chemically intractable structures. Multi-trillion-scale make-on-demand libraries guarantee synthetic feasibility, but conventional virtual screening cannot efficiently navigate these vast spaces or address multi-parameter optimization. We introduce Hyper Screening X, a generative AI framework integrating structure-based design with automated synthesis hardware. By encoding deterministic reaction logic in a generative flow network, the framework evaluates only 10 million candidates to navigate an 11-trillion-compound space, jointly optimizing physicochemical properties while ensuring compatibility with automated synthesis. Prospective validation against an SLC1A5 variant with a cryptic interface yielded a 96% synthesis success rate and a 50% functional hit rate, identifying two first-in-class lead compounds. This synthesis-aware strategy advances autonomous, closed-loop drug discovery.
Open AccessSynthesis-aware generative design in trillion-scale chemical spaces for automated drug discovery
Autonomous drug discovery via generative molecular design is critically bottlenecked by the production of chemically intractable structures. Multi-trillion-scale make-on-demand libraries guarantee synthetic feasibility, but conventional virtual screening cannot efficiently navigate these vast spaces or address multi-parameter optimization. We introduce Hyper Screening X, a generative AI framework integrating structure-based design with automated synthesis hardware. By encoding deterministic reaction logic in a generative flow network, the framework evaluates only 10 million candidates to navigate an 11-trillion-compound space, jointly optimizing physicochemical properties while ensuring compatibility with automated synthesis. Prospective validation against an SLC1A5 variant with a cryptic interface yielded a 96% synthesis success rate and a 50% functional hit rate, identifying two first-in-class lead compounds. This synthesis-aware strategy advances autonomous, closed-loop drug discovery.
- Open Access
- 15 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Macrophage trained immunity requires a mitochondrial glutamine-restriction checkpoint for antitumor protection in mice
- 15 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMacrophage trained immunity requires a mitochondrial glutamine-restriction checkpoint for antitumor protection in mice
- Top Cited PapersOpen Access
- 30 April 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (4) , 1128-1148
Metabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy
Metabolic rewiring, a defining hallmark of cancer, sustains cell proliferation and biosynthesis while coordinating adaptive interactions within the tumor microenvironment (TME). Recent advances reveal that metabolism in the TME-comprising stromal, immune and endothelial components forms a complex metabolic network in which intercellular competition, cooperation and plasticity profoundly influence tumor progression and therapeutic responses. Here we integrate emerging evidence on the organizational principles of amino acid and lipid metabolism within the TME, emphasizing how nutrient fluxes shape immune evasion, therapeutic resistance and metabolic symbiosis. We highlight key mechanisms through which cancer and nonmalignant cells engage in reciprocal nutrient manipulation, focusing on glutamine, arginine, tryptophan, branched-chain amino acids and lipids. The dual roles of these metabolites in immune regulation and tumor growth reveal the limitations of traditional single-pathway targeting and advocate for a network-centric therapeutic approach. We further discuss how metabolite-derived signaling and epigenetic regulation reinforce cell state transitions and immune suppression. Current and emerging therapeutic strategies, including multitarget combinations and immune–metabolic synergies, are evaluated alongside translational challenges. Finally, we underscore the need for spatial metabolomics, liquid biopsy platforms and artificial intelligence-driven modeling to map nutrient competition and cooperative exchange within the TME, offering new opportunities for precision metabolic interventions.
- 30 April 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (4) , 1128-1148
Top Cited PapersOpen AccessMetabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy
Metabolic rewiring, a defining hallmark of cancer, sustains cell proliferation and biosynthesis while coordinating adaptive interactions within the tumor microenvironment (TME). Recent advances reveal that metabolism in the TME-comprising stromal, immune and endothelial components forms a complex metabolic network in which intercellular competition, cooperation and plasticity profoundly influence tumor progression and therapeutic responses. Here we integrate emerging evidence on the organizational principles of amino acid and lipid metabolism within the TME, emphasizing how nutrient fluxes shape immune evasion, therapeutic resistance and metabolic symbiosis. We highlight key mechanisms through which cancer and nonmalignant cells engage in reciprocal nutrient manipulation, focusing on glutamine, arginine, tryptophan, branched-chain amino acids and lipids. The dual roles of these metabolites in immune regulation and tumor growth reveal the limitations of traditional single-pathway targeting and advocate for a network-centric therapeutic approach. We further discuss how metabolite-derived signaling and epigenetic regulation reinforce cell state transitions and immune suppression. Current and emerging therapeutic strategies, including multitarget combinations and immune–metabolic synergies, are evaluated alongside translational challenges. Finally, we underscore the need for spatial metabolomics, liquid biopsy platforms and artificial intelligence-driven modeling to map nutrient competition and cooperative exchange within the TME, offering new opportunities for precision metabolic interventions.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Figure S10, Figure S11 from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Supplementary Figures and Figure Legends for S1 to S11
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Figure S10, Figure S11 from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Supplementary Figures and Figure Legends for S1 to S11
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC.Significance:Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC.Significance:Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- Open Access
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-25
Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var
The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibitors targeting SLC1A5_var has remained a significant challenge. Here, we introduce iMQT_020, a selective allosteric inhibitor identified through structure-based screening. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. Mechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. Additionally, iMQT_020 treatment epigenetically upregulates PD-L1 expression, enhancing the efficacy of combination therapies with anti-PD-L1 immune checkpoint inhibitors. These findings highlight the therapeutic potential of targeting SLC1A5_var as a critical metabolic vulnerability in cancer and demonstrate that targeting allosteric interprotomer interactions is a novel and promising therapeutic strategy for cancer treatment.
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-25
Open AccessTargeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var
The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibitors targeting SLC1A5_var has remained a significant challenge. Here, we introduce iMQT_020, a selective allosteric inhibitor identified through structure-based screening. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. Mechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. Additionally, iMQT_020 treatment epigenetically upregulates PD-L1 expression, enhancing the efficacy of combination therapies with anti-PD-L1 immune checkpoint inhibitors. These findings highlight the therapeutic potential of targeting SLC1A5_var as a critical metabolic vulnerability in cancer and demonstrate that targeting allosteric interprotomer interactions is a novel and promising therapeutic strategy for cancer treatment.
- 26 June 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 661, 124386
Polysaccharide-based emulsion gels for the prevention of postoperative adhesions and as a drug delivery system using 5-fluorouracil
- 26 June 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 661, 124386
Polysaccharide-based emulsion gels for the prevention of postoperative adhesions and as a drug delivery system using 5-fluorouracil
- Open Access
- 1 June 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (6) , 1076-1089
Nutrient sensors and their crosstalk
The macronutrients glucose, lipids, and amino acids are the major components that maintain life. The ability of cells to sense and respond to fluctuations in these nutrients is a crucial feature for survival. Nutrient-sensing pathways are thus developed to govern cellular energy and metabolic homeostasis and regulate diverse biological processes. Accordingly, perturbations in these sensing pathways are associated with a wide variety of pathologies, especially metabolic diseases. Molecular sensors are the core within these sensing pathways and have a certain degree of specificity and affinity to sense the intracellular fluctuation of each nutrient either by directly binding to that nutrient or indirectly binding to its surrogate molecules. Once the changes in nutrient levels are detected, sensors trigger signaling cascades to fine-tune cellular processes for energy and metabolic homeostasis, for example, by controlling uptake, de novo synthesis or catabolism of that nutrient. In this review, we summarize the major discoveries on nutrient-sensing pathways and explain how those sensors associated with each pathway respond to intracellular nutrient availability and how these mechanisms control metabolic processes. Later, we further discuss the crosstalk between these sensing pathways for each nutrient, which are intertwined to regulate overall intracellular nutrient/metabolic homeostasis.
- 1 June 2023
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 55 (6) , 1076-1089
Open AccessNutrient sensors and their crosstalk
The macronutrients glucose, lipids, and amino acids are the major components that maintain life. The ability of cells to sense and respond to fluctuations in these nutrients is a crucial feature for survival. Nutrient-sensing pathways are thus developed to govern cellular energy and metabolic homeostasis and regulate diverse biological processes. Accordingly, perturbations in these sensing pathways are associated with a wide variety of pathologies, especially metabolic diseases. Molecular sensors are the core within these sensing pathways and have a certain degree of specificity and affinity to sense the intracellular fluctuation of each nutrient either by directly binding to that nutrient or indirectly binding to its surrogate molecules. Once the changes in nutrient levels are detected, sensors trigger signaling cascades to fine-tune cellular processes for energy and metabolic homeostasis, for example, by controlling uptake, de novo synthesis or catabolism of that nutrient. In this review, we summarize the major discoveries on nutrient-sensing pathways and explain how those sensors associated with each pathway respond to intracellular nutrient availability and how these mechanisms control metabolic processes. Later, we further discuss the crosstalk between these sensing pathways for each nutrient, which are intertwined to regulate overall intracellular nutrient/metabolic homeostasis.
- 3 January 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5) , 735-752
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- 3 January 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5) , 735-752
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- Open Access
- 21 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Author Correction: O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine
- 21 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Open AccessAuthor Correction: O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine